ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421" (Q62090309)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

title

Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421" (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

author name string

H Gavras

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

J Biollaz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

B Waeber

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

H R Brunner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

I Gavras

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

R O Davies

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

language of work or name

English

0 references

publication date

1 September 1981

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

issue

8246

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

page(s)

543-547

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in Man

27 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Converting enzyme inhibition with an orally active compound in hypertensive man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Improvement of chronic congestive heart-failure by oral captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Treatment of Chronic Congestive Heart Failure with Captopril, an Oral Inhibitor of Angiotensin-Converting Enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Nephrotic syndrome in patient on captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Captopril and agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Fatal Pancytopenia Associated with the Use of Captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Adverse effects of D-penicillamine in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

A new class of angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

The renin system: Variations in man measured by radioimmunoassay or bioassay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Estimation of angiotensin II concentration in human plasma by radioimmunoassay. Some applications to physiological and clinical states.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Disposition of captopril in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Accentuated Vascular and Endocrine Response to Sq 20881 in Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Differences in response to the peptidyldipeptide hydrolase inhibitors SQ 20,881 and SQ 14,225 in normal-renin essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Acute and chronic effect of captropril in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effects on blood pressure and its use to identify and treat the renin factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Increased Glomerular Filtration Rate after Converting-Enzyme Inhibition in Essential Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

Effect of Captopril on Renal Vascular Tone in Patients with Essential Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2990937-5

7 January 2021

10.1016/S0140-6736(81)90937-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6116000%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

1 reference